[go: up one dir, main page]

NO20064510L - Oral mosidomin sammensetning med vedvarende frigjoring - Google Patents

Oral mosidomin sammensetning med vedvarende frigjoring

Info

Publication number
NO20064510L
NO20064510L NO20064510A NO20064510A NO20064510L NO 20064510 L NO20064510 L NO 20064510L NO 20064510 A NO20064510 A NO 20064510A NO 20064510 A NO20064510 A NO 20064510A NO 20064510 L NO20064510 L NO 20064510L
Authority
NO
Norway
Prior art keywords
composition
mosidomin
oral
sustained release
molsidomin
Prior art date
Application number
NO20064510A
Other languages
English (en)
Other versions
NO336913B1 (no
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Ltd filed Critical Therabel Pharmaceuticals Ltd
Publication of NO20064510L publication Critical patent/NO20064510L/no
Publication of NO336913B1 publication Critical patent/NO336913B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Anvendelse av molsidomin eller ett av dets farmasøytisk akseptable salter, som er anvendelige innen den farmasøytiske industri, spesielt i form av en peroral fast sammensetning med vedvarende frigjøring med effekt i 24 timer, for fremstilling av et medikament til forhindring eller reduksjon av utviklingen av aterosklerose.
NO20064510A 2004-04-05 2006-10-04 Anvendelse av molsidomin eller ett av dets farmasøytisk akseptable salter, i form av en oral fast sammensetning NO336913B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403534A FR2868314B1 (fr) 2004-04-05 2004-04-05 Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
PCT/EP2005/003531 WO2005107761A1 (fr) 2004-04-05 2005-04-01 Composition orale de la molsidomine a liberation prolongee pour le traitement de l’atherosclerose

Publications (2)

Publication Number Publication Date
NO20064510L true NO20064510L (no) 2006-10-31
NO336913B1 NO336913B1 (no) 2015-11-23

Family

ID=34944920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064510A NO336913B1 (no) 2004-04-05 2006-10-04 Anvendelse av molsidomin eller ett av dets farmasøytisk akseptable salter, i form av en oral fast sammensetning

Country Status (28)

Country Link
US (1) US7754715B2 (no)
EP (1) EP1732565B8 (no)
JP (1) JP5117847B2 (no)
KR (1) KR101162385B1 (no)
CN (1) CN1938032B (no)
AU (1) AU2005239799B2 (no)
BE (1) BE1016580A3 (no)
BR (1) BRPI0509642A (no)
CA (1) CA2562287C (no)
CY (1) CY1117614T1 (no)
DK (1) DK1732565T3 (no)
ES (1) ES2567576T3 (no)
FR (1) FR2868314B1 (no)
HR (1) HRP20160479T1 (no)
HU (1) HUE029199T2 (no)
IL (1) IL178440A0 (no)
IT (1) ITTO20050220A1 (no)
MA (1) MA28518B1 (no)
MD (1) MD4080C1 (no)
NO (1) NO336913B1 (no)
NZ (1) NZ550341A (no)
PL (1) PL1732565T3 (no)
RS (1) RS54791B1 (no)
RU (1) RU2388475C2 (no)
SI (1) SI1732565T1 (no)
UA (1) UA88461C2 (no)
WO (1) WO2005107761A1 (no)
ZA (1) ZA200608219B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617494T3 (es) * 2012-05-31 2017-06-19 G. Pohl-Boskamp Gmbh & Co. Kg Inducción de arteriogénesis con un donador de óxido nítrico tal como nitroglicerina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
KR100464876B1 (ko) * 2001-11-15 2005-01-06 학교법인 인제학원 동충하초의 코르디세핀을 함유하는 항혈전제 조성물
WO2010062256A1 (en) * 2008-11-27 2010-06-03 Nanyang Polytechnic Process and system for automatic identification of the larvae of aedes albopictus and aedes aegypti

Also Published As

Publication number Publication date
ITTO20050220A1 (it) 2005-10-06
BRPI0509642A (pt) 2007-09-18
CY1117614T1 (el) 2017-04-26
EP1732565B8 (fr) 2016-05-11
CN1938032B (zh) 2010-06-09
US20070212413A1 (en) 2007-09-13
HRP20160479T1 (hr) 2016-06-03
NZ550341A (en) 2009-11-27
MD4080C1 (ro) 2011-07-31
UA88461C2 (ru) 2009-10-26
SI1732565T1 (sl) 2016-06-30
MA28518B1 (fr) 2007-04-03
MD4080B1 (en) 2010-12-31
CA2562287C (fr) 2013-05-14
HUE029199T2 (en) 2017-03-28
FR2868314B1 (fr) 2008-10-24
CN1938032A (zh) 2007-03-28
FR2868314A1 (fr) 2005-10-07
HK1092736A1 (zh) 2007-02-16
IL178440A0 (en) 2007-02-11
KR101162385B1 (ko) 2012-07-06
EP1732565B1 (fr) 2016-03-09
EP1732565A1 (fr) 2006-12-20
AU2005239799A1 (en) 2005-11-17
RU2388475C2 (ru) 2010-05-10
CA2562287A1 (fr) 2005-11-17
WO2005107761A1 (fr) 2005-11-17
ES2567576T3 (es) 2016-04-25
BE1016580A3 (fr) 2007-02-06
NO336913B1 (no) 2015-11-23
AU2005239799B2 (en) 2010-12-23
RU2006134695A (ru) 2008-05-20
RS54791B1 (sr) 2016-10-31
PL1732565T3 (pl) 2016-08-31
KR20070015534A (ko) 2007-02-05
US7754715B2 (en) 2010-07-13
JP2007531781A (ja) 2007-11-08
JP5117847B2 (ja) 2013-01-16
ZA200608219B (en) 2008-02-27
DK1732565T3 (en) 2016-05-09

Similar Documents

Publication Publication Date Title
CY1126116T1 (el) Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη
CU23551B7 (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
WO2006127738A3 (en) Compressible chewing gums for delivery of actives
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
MX2010004323A (es) Formas de dosificacion oral que comprenden acetato de licarbazepina.
ECSP055568A (es) Composición de comprimido de liberación sostenida de pramipexol
NO20051389L (no) Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler
NO20014035L (no) System for oral administrasjon av medikament
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
CO6612204A2 (es) Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
UA86622C2 (ru) Фармацевтическая композиция, которая диспергируется в ротовой полости, для введения в слизистую оболочку ротовой полости или подъязычного введения агомелатина
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
MA31445B1 (fr) Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
DK1746980T3 (da) Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
NO20062491L (no) Benzoksazinderivter og deres anvendelse
IL186862A0 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
NO20050771L (no) Bicifadinformulering
NO20064510L (no) Oral mosidomin sammensetning med vedvarende frigjoring